☆ 4.6 Review

COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic

BIOLOGY-BASEL (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Molnupiravir is effective in patients with haematological malignancies

Lukasz Bolkun et al.

Summary: Patients with hematologic malignancies are at high risk of severe infectious complications and death from SARS-CoV-2 infection. Their immune deficits and the treatment used make COVID-19 vaccination less effective. Molnupiravir has shown significant benefits in reducing hospitalization and death in COVID-19 patients, including those with hematologic malignancies.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Hematology

Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis

Matthew Ho et al.

Summary: Patients with multiple myeloma have a lower efficacy from COVID-19 vaccination and a high rate of mortality from COVID-19 in hospitalized patients. The study found a relatively low infection rate but a quarter of the COVID-19 infections were severe. Treatment with CD38 antibody, cardiac and pulmonary comorbidities were independent predictors for ICU admission. Cardiac comorbidity was an independent predictor of mortality, while MM/AL in remission was associated with lower mortality.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Reply to successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era

Ramona Cassin et al.

Summary: This is a multicentre study on the early administration of anti-SARS-CoV-2 neutralizing antibodies among patients with hematological malignancies and early-stage COVID-19. The study validates the safety and efficacy of this treatment in terms of alleviating infection course and decreasing mortality.

HEMATOLOGICAL ONCOLOGY (2023)

Add to Collection

Review Urology & Nephrology

Therapeutic advances in COVID-19

Naoka Murakami et al.

Summary: This article evaluates different types of therapies for treating COVID-19, with a particular focus on their relevance to patients with kidney failure and kidney transplant recipients. The research finds that anti-inflammatory and antiviral agents have a stronger evidence base and greater benefits compared to other therapeutic approaches.

NATURE REVIEWS NEPHROLOGY (2023)

Add to Collection

Review Hematology

Convalescent plasma and COVID-19: Time for a second-second look?

Michael J. Joyner et al.

Summary: In this short narrative, we provide an overview of our experiences leading the US Convalescent Plasma Program in the spring and summer of 2020. We summarize the emergence of the program and the high-level lessons we learned. Additionally, we share our impressions and ideas on the use of convalescent plasma at scale in the United States early in the pandemic and its potential applications in future outbreaks of novel infectious diseases.

TRANSFUSION MEDICINE (2023)

Add to Collection

Article Immunology

Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial

Saoussen Ben Abdallah et al.

Summary: Zinc supplementation benefits COVID-19 patients by reducing mortality rate, intensive care unit admission rate, and symptom duration.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Review Medicine, General & Internal

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

Queenie Fernandes et al.

Summary: The emergence of novel and evolving variants of SARS-CoV-2 has created the need for newer and more adaptive diagnostic methods. However, developing rapid and sensitive diagnostic technologies has become more challenging due to emerging variants and varying symptoms. Vaccines and drugs are essential for prevention and protection, and constant development is underway. This review discusses the challenges posed by novel variants and the evolution of diagnostic techniques, as well as the development, mechanisms, advantages, and drawbacks of vaccines and drugs and their immunological impact.

ANNALS OF MEDICINE (2022)

Add to Collection

Article Hematology

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Livio Pagano et al.

BLOOD (2022)

Add to Collection

Review Hematology

COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research

Lindsey Wang et al.

Summary: This study shows that among the fully vaccinated population, patients with hematologic malignancies (HM) had a significantly higher risk for breakthrough infections compared to patients without cancer. Breakthrough infections in patients with HM were associated with higher rates of hospitalization and mortality.

BLOOD REVIEWS (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Microbiology

Pharmacological treatment of COVID-19: an opinion paper

A. Garcia-Lledo et al.

Summary: The early maturity and effectiveness of the developed COVID-19 vaccines have been the most significant and life-saving breakthrough against the pandemic. Despite the development of vaccines, there has been a continuous search for therapeutic drugs throughout the pandemic. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid aims to provide an early, simplified, and critical approach to these new drugs, developments in immunotherapy, and known immune response modulators effective against the virus to help understand the current situation.

REVISTA ESPANOLA DE QUIMIOTERAPIA (2022)

Add to Collection

Article Cell Biology

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

William A. Fischer et al.

Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Oncology

Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies

Christina Y. Lee et al.

Summary: Persistent COVID-19 infection is more likely to occur in patients with hematologic malignancies, particularly B-cell lymphomas. Active therapy and diminished T-cell counts are associated with acute mortality, while B cell-depleting therapy is the main cause of rehospitalization. Patients with persistent infection show high viral entropy, especially those with impaired CD8(+) T-cell immunity. These findings highlight the need for additional therapeutic strategies to clear the virus in immunocompromised patients.

CANCER DISCOVERY (2022)

Add to Collection

Article Infectious Diseases

Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases

Oskar Ljungquist et al.

Summary: This study described the clinical and virological treatment outcomes of a group of severely immunosuppressed patients with COVID-19 who received convalescent plasma treatment. Results showed that some patients improved clinically after CCP treatment, but caution should be taken in interpreting the results due to limitations in the study design. Prospective, randomized trials are needed for further investigation.

INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient

Mikael Kajova et al.

Summary: This article presents a case of a lymphoma patient with COVID-19 who was successfully treated with remdesivir, along with a literature review of similar cases. The study found that the clinical course of COVID-19 in lymphoma patients may be protracted and may lack a humoral immune response.

INFECTIOUS DISEASES (2022)

Add to Collection

Article Oncology

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

Bartosz Pula et al.

Summary: SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.

CANCERS (2022)

Add to Collection

Article Hematology

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Carlo Visco et al.

Summary: This study investigated the clinical behavior and clinical parameters of lymphoma patients with COVID-19, with the aim of identifying predictors of death. The results showed that lymphoma patients had poor outcomes when diagnosed with COVID-19, but treatment for lymphoma did not impact survival. The study also identified four easy-to-use factors associated with the risk of death.

BLOOD ADVANCES (2022)

Add to Collection

Article Biology

Elements and COVID-19: A Comprehensive Overview of Studies on Their Blood/Urinary Levels and Supplementation with an Update on Clinical Trials

Agnieszka Scibior et al.

Summary: This review provides information on various aspects of COVID-19, including clinical features, treatment options, sociodemographic factors, and the importance and levels of minerals in the disease.

BIOLOGY-BASEL (2022)

Add to Collection

Article Oncology

The outcome of COVID-19 in patients with hematological malignancy

Pinar Tiglioglu et al.

Summary: The study aimed to investigate the impact of COVID-19 on patients with hematological cancer, with a focus on factors affecting mortality. Results showed that COVID-19 affected patients with myeloproliferative neoplasms, non-Hodgkin lymphoma, and multiple myeloma more frequently. Low hemoglobin and platelet levels were identified as contributing factors to mortality, highlighting the importance of protective measures and vaccination for this vulnerable patient population.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 vaccination and breakthrough infections in patients with cancer

A. L. Schmidt et al.

Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Hematology

COVID-19 in patients with hematologic malignancy

Petra Langerbeins et al.

BLOOD (2022)

Add to Collection

Article Hematology

Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies

Akio Mori et al.

Summary: This study investigates the response to COVID-19 vaccination in patients with myeloid malignancies. The findings suggest that most patients with myeloid malignancies develop an immune response to the vaccine, but leukemia patients may have lower antibody levels. This indicates that the response to the vaccine may be related to disease subtype and treatment status.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Oncology

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver et al.

CANCER CELL (2022)

Add to Collection

Article Medicine, General & Internal

Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

Semih Basci et al.

Summary: This study retrospectively investigated data from 926 COVID-19 patients, highlighting that patients with hematologic cancers have a more severe course of the disease, higher rates of ICU admission, MV assistance, longer hospital stays, and a higher case fatality rate compared to patients with solid cancers.

INTERNAL AND EMERGENCY MEDICINE (2022)

Add to Collection

Letter Hematology

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Sabina Chiaretti et al.

Summary: The management of patients with hematologic malignancies, particularly acute lymphoblastic leukemia (ALL), during the COVID-19 pandemic is challenging. This cross-sectional observational study conducted in Italian hematology centers explored the characteristics and management of COVID-19-infected ALL patients.

HAEMATOLOGICA (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Anil Gupta et al.

Summary: The study showed that sotrovimab treatment significantly reduced the risk of all-cause hospitalization or death in nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression. Sotrovimab also decreased the risk of emergency department visits, hospitalization, or death, as well as the progression to severe or critical respiratory COVID-19. Adverse events were similar between the treatment and placebo groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Review Medical Laboratory Technology

Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis

Adel Naimi et al.

Summary: Hematologic cancer patients are more susceptible to severe COVID-19, requiring attention to oxygen therapy and anticoagulant treatment. Common symptoms include fever, cough, and fatigue, while hypertension and dyslipidemia are common comorbidities. The mortality rate among these patients is 21.34%.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2022)

Add to Collection

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader et al.

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Correction Oncology

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) (Apr, 10.1038/s41375-022-01556-7, 2022)

Georg Maschmeyer et al.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Myron J. Levin et al.

Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

Deniz C. Guven et al.

Summary: Patients with hematologic malignancies, especially those with CLL and those receiving specific treatments, have significantly lower seroconversion rates after SARS-CoV-2 vaccination. Effective strategies are urgently needed to improve vaccine efficacy in these vulnerable populations.

ONCOLOGIST (2022)

Add to Collection

Article Immunology

COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients

Catherine DeVoe et al.

Summary: In this single-center retrospective cohort study, there was no difference in the severity of COVID-19 disease between vaccinated and unvaccinated patients with hematologic malignancies. Recent anti-B-cell therapy was associated with more severe illness.

TRANSPLANT INFECTIOUS DISEASE (2022)

Add to Collection

Review Immunology

Molnupiravir and Its Antiviral Activity Against COVID-19

Lili Tian et al.

Summary: Molnupiravir is a broad-spectrum antiviral drug with the potential to treat and prevent various coronaviruses, including SARS-CoV-2. Clinical trials have shown its beneficial effects and favorable safety profile for mild to moderate COVID-19 patients. Molnupiravir has the potential to be a therapeutic candidate against COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review

Diego Fernandez-Lazaro et al.

Summary: This is a systematic review evaluating the effect and safety of convalescent plasma therapy on hospitalized COVID-19 patients. The results show that convalescent plasma therapy can reduce viral load, symptomatology, the period of infection, and mortality without serious adverse effects.

PHARMACEUTICS (2022)

Add to Collection

Article Immunology

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

M. Veronica Dioverti et al.

Summary: B-cell-depleted patients with prolonged COVID-19 infection, caused by the inability to generate sufficient humoral response to clear the virus, were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Hematology

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Ferenc Magyari et al.

Summary: In this study, the combination of remdesivir and convalescent plasma therapy was found to be efficient and safe for the treatment of COVID-19 in patients with hematological malignancies and B-cell lymphopenia. This combined treatment reduced the need for oxygen support, length of hospital stay, and viral positivity.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Tixagevimab plus Cilgavimab: First Approval

Susan J. Keam

Summary: Tixagevimab + cilgavimab is a monoclonal antibody combination developed by AstraZeneca for the prevention and treatment of COVID-19. It has been approved in the UK and EU for the prevention of COVID-19 in certain populations. Additionally, it has received Emergency Use Authorization from the US FDA.

DRUGS (2022)

Add to Collection

Review Virology

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir

Karolina Akinosoglou et al.

Summary: The protease inhibitor nirmatrelvir coupled with ritonavir has shown promise in preventing disease progression in high-risk COVID-19 patients. Real-world data support the efficacy and safety of this oral antiviral agent, although potential resistance issues need further investigation.

VIRUSES-BASEL (2022)

Add to Collection

Article Medicine, General & Internal

Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma

Yayoi Ueda et al.

Summary: An individual with follicular lymphoma experienced prolonged COVID-19, with exacerbation of symptoms after initial transient improvement. The patient recovered with remdesivir and dexamethasone treatment, but no anti-spike protein IgG was detected after completing a primary series of SARS-CoV-2 vaccinations. Careful observation and appropriate chemotherapy based on disease status and lymphoma type are necessary for immunocompromised patients.

INTERNAL MEDICINE (2022)

Add to Collection

Review Pharmacology & Pharmacy

Efficacy and safety profile of corticosteroids and non-steroidal anti-inflammatory drugs in COVID-19 management: A narrative review

Seth Kwabena Amponsah et al.

Summary: This article discusses the clinical effects of using non-steroidal anti-inflammatory drugs and corticosteroids in the treatment of COVID-19. Studies have shown that methylprednisolone, dexamethasone, and ibuprofen have therapeutic potential in reducing mortality in COVID-19 patients. Additionally, the use of NSAIDs is not associated with adverse outcomes of COVID-19.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Immunology

Association of COVID-19 mortality with serum selenium, zinc and copper: Six observational studies across Europe

Kamil Demircan et al.

Summary: In COVID-19 patients in Europe, serum levels of selenium and zinc are associated with mortality risk, with lower levels observed in non-survivors.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 in Patients with Hematologic Diseases

Ilaria Carola Casetti et al.

Summary: The COVID-19 outbreak has greatly impacted patients with hematologic diseases whose immune systems may be compromised due to treatments. Hematologic malignancies have emerged as a risk factor for severe COVID-19 infection, emphasizing the importance of vaccination for these patients.

BIOMEDICINES (2022)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery et al.

Summary: This study evaluated the safety and efficacy of tixagevimab-cilgavimab in preventing severe COVID-19 or death in non-hospitalized adults. The results showed that a single dose of tixagevimab-cilgavimab significantly reduced the risk of progression to severe COVID-19 or death, with favorable safety.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Hematology

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies

Anthony J. Ocon et al.

Summary: This study assessed the effectiveness of tixagevimab and cilgavimab in preventing symptomatic infection in immunocompromised patients with hematological malignancy. The results showed that these patients had a low incidence of symptomatic infection or hospitalization, suggesting the potential efficacy of the antibody combination in this high-risk population.

JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Letter Hematology

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Jon Salmanton-Garcia et al.

HEMASPHERE (2022)

Add to Collection

Article Oncology

Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin

Erin A. Dean et al.

Summary: This case report describes the successful treatment of an elderly woman with refractory acute myeloid leukemia (AML) who also had mild COVID-19 infection. The patient received antiviral therapy and COVID-19 management during chemotherapy. The case highlights the importance of considering timely chemotherapy in appropriate patients with aggressive hematologic malignancies and concomitant SARS-CoV-2 infections.

CASE REPORTS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano et al.

Summary: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-SARS-CoV-2 vaccination. This study found a relatively low mortality rate among patients with breakthrough COVID-19, with the Omicron variant being the predominant strain. Patients receiving monoclonal antibody treatment had a lower mortality rate.

BLOOD (2022)

Add to Collection

Review Infectious Diseases

Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review

Andrew Ustianowski

Summary: This article emphasizes the importance of the tixagevimab/cilgavimab combination in protecting vulnerable individuals who cannot receive full vaccination or have a poor response to vaccines. The article discusses the ability of this treatment to neutralize emerging variants, appropriate dosage in vulnerable populations, and the impact of prior vaccination on treatment effectiveness.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

Add to Collection

Article Oncology

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy

Jerzy Jaroszewicz et al.

Summary: Patients with active malignancies have a higher risk of severe SARS-CoV-2 infection, but early treatment with remdesivir can significantly reduce the 28-day in-hospital mortality. Poor kidney function and low baseline peripheral oxygen saturation worsen the prognosis, emphasizing the importance of kidney protection and early hospitalization.

CANCERS (2022)

Add to Collection

Review Environmental Sciences

The effect of zinc supplementation on the course of COVID-19-A systematic review and meta-analysis

Monika Olczak-Pruc et al.

Summary: The objective of this study was to determine the antiviral effect of zinc administration in COVID-19 patients. The results showed that zinc supplementation was associated with lower in-hospital mortality in COVID-19 patients and had no negative side effects. Therefore, zinc supplementation should be considered as an adjunct therapy for COVID-19 patients.

ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

Use of remdesivir for COVID-19 in patients with hematologic cancer

Alexandra Martin-Onraet et al.

Summary: Patients with hematologic malignancies (HM) remain at high risk of complications when infected with COVID-19. The use of remdesivir did not reduce the risk of disease progression in hospitalized patients but showed no severe COVID-19 cases or deaths in patients receiving remdesivir in outpatient settings.

CLINICAL AND EXPERIMENTAL MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.

LANCET (2022)

Add to Collection

Article Oncology

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

Sean H. Lim et al.

Summary: Patients with hematological malignancies, especially those undergoing active anticancer treatment or on anti-CD20 therapy, show compromised immune responses to COVID-19 vaccination. However, booster vaccination can significantly improve antibody responses in indolent B-cell lymphoma patients, and antigen-specific T-cell responses are observed in the majority of patients after a third dose, regardless of their cancer treatment status.

NATURE CANCER (2022)

Add to Collection

Article Oncology

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

Francesca Romana Mauro et al.

Summary: Pneumococcal vaccination response was analyzed in 112 CLL patients, with factors like age, IgG levels, prior treatment, and disease progression being associated with lower immune response rates. Age ≥ 60 years, IgG levels < 400 mg/L, prior treatment, and signs of disease progression were linked to a decreased response rate.

LEUKEMIA (2021)

Add to Collection

Review Infectious Diseases

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Ibai Los-Arcos et al.

Summary: CAR-T cell therapy is a promising treatment for B-cell malignancies, with two products approved for aggressive B-cell lymphoma and acute lymphoblastic leukemia. Patients receiving CAR-T therapy often develop fever post-infusion, mainly due to cytokine release syndrome.

INFECTION (2021)

Add to Collection

Review Oncology

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Heinz Ludwig et al.

Summary: Vaccination is crucial for patients with multiple myeloma due to their increased risk of infections from immune suppression. Adequate measures should be taken to stimulate effective immune responses, and some patients may require a broader spectrum of vaccinations.

LEUKEMIA (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19

Joydeb Majumder et al.

Summary: This review provides a summary of the latest approaches to diagnostics and therapy of COVID-19, focusing on conventional treatments including antiviral drugs, vaccines, antibody treatments, convalescent plasma therapy, as well as nanoparticle-based approaches. Extensive research and clinical trials are currently ongoing for these treatments in the fight against COVID-19.

AAPS JOURNAL (2021)

Add to Collection

Review Allergy

Risk factors for severe and critically ill COVID-19 patients: A review

Ya-dong Gao et al.

Summary: The severity factors of COVID-19 include age, gender, underlying health conditions such as hypertension, diabetes, obesity, and immunodeficiency, which may lead to complications like acute kidney injury. Various laboratory indicators and parameters can help monitor disease progression, while socioeconomic factors, lifestyle, and quality of healthcare also play a role in individual outcomes.

ALLERGY (2021)

Add to Collection

Review Medicine, Research & Experimental

COVID-19 challenges and its therapeutics

Sabi Ur Rehman et al.

Summary: COVID-19 has emerged as a major cause of death worldwide, prompting extensive research into therapeutic options including drug repurposing and repositioning, as well as exploration of various medications and medicinal plants for potential treatment. Vaccine development is also underway, with concerns about SARS-CoV-2 variants impacting vaccine effectiveness.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Review Infectious Diseases

CAR-T cell therapy and infection: a review

Olivia Bupha-Intr et al.

Summary: Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression and treatment-specific toxicities, highlighting the importance of infection prevention strategies. Ongoing surveillance and effective prophylaxis are essential to support safe and effective patient care in the rapid adoption of CAR-T cell therapy.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Add to Collection

Review Pharmacology & Pharmacy

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

Sylwester Drozdzal et al.

Summary: The COVID-19 pandemic poses a significant threat to global health with various therapeutic agents initially proclaimed to be effective, but later disproved. The Pfizer agent PAXLOVIDTM has shown promising results in reducing hospitalization time and death rates. Further development of additional treatments is needed due to the insufficiency of current recommended therapeutic options.

DRUG RESISTANCE UPDATES (2021)

Add to Collection

Article Oncology

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

Silvia Ferrari et al.

Summary: This study described the use of hyperimmune plasma therapy in immunocompromised patients with hematological disorders during the SARS-CoV-2 outbreak, showing positive outcomes such as clinical improvement, recovery, and viral clearance. While further research is needed, the results suggest a specific role for hyperimmune plasma therapy in hematological patients.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)

Jennifer A. Whitaker et al.

Summary: Among patients with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL), the immunogenicity of high-dose influenza vaccine is lower compared to healthy adults, with MBL patients showing greater immunogenicity against influenza B compared to CLL patients.

VACCINE (2021)

Add to Collection

Review Immunology

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates

Takehiro Ura et al.

Summary: The pandemic has accelerated vaccine development; new vaccine platforms and immunological endpoints are crucial for vaccine efficacy evaluation; updated information on individual immunological features guides effective vaccine development strategies.

VACCINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou et al.

Summary: Patients with CLL are more susceptible to the impact of COVID-19, with age, CLL-directed treatment, and cardiac failure being significant risk factors for outcomes. Untreated patients have a better chance of survival, and age, cardiac failure, and CLL-directed treatment are significant risk factors for OS.

LEUKEMIA (2021)

Add to Collection

Letter Oncology

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart et al.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort

Talvinder Bhogal et al.

Summary: This multi-center retrospective UK audit investigated cancer patients who had SARS-CoV-2 infection and found that patients with haematological malignancies and nosocomial transmission were at increased risk of death. Urgent reassessment of shielding advice, reinforcement of stringent infection control, and regular testing of patients and staff are necessary to prevent nosocomial transmission.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Preethi Jeyaraman et al.

Summary: This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Hematology

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy

Remy Dulery et al.

Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Review Immunology

COVID-19 Mechanisms in the Human Body-What We Know So Far

Ashutosh Kumar et al.

Summary: Since the onset of the COVID-19 pandemic, extensive experimental studies have been conducted globally, resulting in a vast accumulation of scientific knowledge on the virus mechanisms and variants, transforming the outlook from despair to hope. However, there are still many knowledge gaps to be addressed, and the emergence of new variants poses greater challenges.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors

Daniele Cattaneo et al.

Summary: BCR-ABL1-negative myeloproliferative neoplasms have a reduced life expectancy mainly due to an increased risk of thrombo-hemorrhagic events, fibrotic progression/leukemic evolution, and infectious complications. JAK2V617F is the main driver mutation in these conditions, and JAK inhibitors, while improving symptoms and quality of life for MPN patients, may also lead to adverse events related to immune suppression or deficiency.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Alessandro Allegra et al.

Summary: Secondary immunodeficiency is common in patients with hematological malignancies, affecting their risk of infection and overall prognosis. Treatment strategies need to be personalized based on individual clinical and immunological conditions, with potential risks associated with vaccination such as decreased immune response and adverse reactions.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Molnupiravir in COVID-19: A systematic review of literature

Awadhesh Kumar Singh et al.

Summary: Molnupiravir has shown significant benefits in reducing hospitalization or death in mild COVID-19 cases, making it a potential important tool in combating SARSCoV-2. However, its efficacy in moderate to severe COVID-19 remains uncertain, requiring further studies for clarification.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

Add to Collection

Article Hematology

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker et al.

BLOOD (2021)

Add to Collection

Article Oncology

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain

Josep-Maria Ribera et al.

Summary: The study compared the characteristics and outcomes of adults with acute lymphoblastic leukemia (ALL) and COVID-19 infection in the first and second waves of the pandemic in Spain. The presence of comorbidities at COVID-19 infection was identified as the only prognostic factor for survival, highlighting the importance of vaccination priority for these patients.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Letter Oncology

Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

Barbora Weinbergerova et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Letter Oncology

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Antonio Cuneo et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)

Noha Sharafeldin et al.

Summary: The largest multicenter cohort of cancer patients with COVID-19 to date was constructed by the U.S. N3C collaboration. It was found that COVID-19 positivity significantly increased the risk of all-cause mortality in cancer patients. Factors such as age, gender, region, comorbidities, and specific cancer types were associated with increased mortality risk in cancer patients with COVID-19.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Lixue Huang et al.

LANCET (2021)

Add to Collection

Article Oncology

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Ilana Levy et al.

Summary: This study found that COVID-19 infection is particularly severe in patients with hematological malignancies. Factors like age over 70, hypertension, and active hematological cancer treatment may increase the risk of severe disease or hospitalization, while remdesivir stands out as the most effective treatment among those examined.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Oncology

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Tomas Palanques-Pastor et al.

Summary: This multicenter observational study found a higher mortality rate in AML patients with SARS-CoV-2 infection. Factors influencing mortality included age, gender, active leukemia, severity of symptoms, etc. Certain medications and biochemical markers may have a protective effect in lowering the mortality rate.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Philippe Begin et al.

Summary: Convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.

NATURE MEDICINE (2021)

Add to Collection

Review Infectious Diseases

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety

Maria Teresa Mascellino et al.

Summary: This review discusses the principal vaccines developed against SARS-CoV-2 during the Covid-19 pandemic, evaluating their mechanisms of action, efficacy, safety, and storage temperature. It also delves into dosing issues, vaccination strategies, monoclonal antibodies, and the challenges posed by virus variants. The review highlights the varying efficacy of different vaccines and emphasizes the importance of vaccination strategies based on age groups to achieve herd immunity quickly.

INFECTION AND DRUG RESISTANCE (2021)

Add to Collection

Review Oncology

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

Jason D. Goldman et al.

Summary: This review examines the impact of SARS-CoV-2 infection on mortality in populations with distinct forms of immunocompromise and discusses the immune dysregulation in COVID-19. It suggests that certain immunosuppressants may have varying effects on different populations, providing insights for the treatment of COVID-19.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Hematology

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma

Erik Gaitzsch et al.

Summary: B-cell depleted lymphoma patients with COVID-19 experienced more severe and prolonged clinical course, with early activation of monocytes/macrophages, neutrophils, and the complement system, exacerbation of inflammatory response, and dysfunctional interferon signaling leading to clinical deterioration. Additionally, these patients showed SARS-CoV-2-specific T-effector cell responses but struggled with long-term viral shedding and inability to sustain lasting antibody responses.

HEMASPHERE (2021)

Add to Collection

Article Hematology

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

Isabel Regalado-Artamendi et al.

Summary: This study examined the impact of COVID-19 on patients with lymphoma, finding that factors like age, confusion, urea concentration, and respiratory rate, as well as active disease, were associated with higher mortality risk. Additionally, continued presence of the virus after week six significantly increased mortality rates.

HEMASPHERE (2021)

Add to Collection

Review Hematology

Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections

Rossana Maffei et al.

BLOOD REVIEWS (2020)

Add to Collection

Article Oncology

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis

Douglas Tremblay et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

First Case of 2019 Novel Coronavirus in the United States

Michelle L. Holshue et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Infection in Advanced Chronic Kidney Disease and Subsequent Adverse Outcomes after Dialysis Initiation: A Nationwide Cohort Study

Chih-Hsiang Chang et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Letter Hematology

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

Gordon Cook et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Letter Hematology

Clinical outcome of coronavirus disease 2019 in haemato-oncology patients

James A. Aries et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Critical Care Medicine

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

Ruchong Chen et al.

CHEST (2020)

Add to Collection

Article Oncology

COVID-19 in persons with chronic myeloid leukaemia

Weiming Li et al.

LEUKEMIA (2020)

Add to Collection

Review Oncology

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Evangelos Terpos et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

COVID-19 in persons with haematological cancers

Wenjuan He et al.

LEUKEMIA (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Compassionate Use of Remdesivir for Patients with Severe Covid-19

J. Grein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies

Jose Maria Sanchez-Pina et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Hematology

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Antonio Cuneo et al.

BLOOD (2020)

Add to Collection

Letter Hematology

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Vallari Shah et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Immunology

Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies

Andrew Kin et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)

Add to Collection

Letter Hematology

COVID-19 in patients with hematological malignancies: A retrospective case series

Maria-Stefania Infante et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)

Add to Collection

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Letter Oncology

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Massimo Breccia et al.

LEUKEMIA (2020)

Add to Collection

Article Pharmacology & Pharmacy

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Spinello Antinori et al.

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

Giuseppe Lippi et al.

RESPIRATORY MEDICINE (2020)

Add to Collection

Article Oncology

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio Garcia-Suarez et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Ludovico Cantuti-Castelvetri et al.

SCIENCE (2020)

Add to Collection

Article Oncology

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Jose Luis Pinana et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

Add to Collection

Article Education, Scientific Disciplines

Updates in infection risk and management in acute leukemia

C. Logan et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

Add to Collection

Letter Medicine, General & Internal

The use of dexamethasone in the treatment of COVID-19

Mohammed Lester et al.

ANNALS OF MEDICINE AND SURGERY (2020)

Add to Collection

Article Hematology

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic

Davide Rossi et al.

HEMASPHERE (2020)

Add to Collection

Article Infectious Diseases

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)

Catherine Cordonnier et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia

Vesa Lindstrom et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)

Add to Collection

Review Hematology

A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia

Tamar Tadmor et al.

EXPERT REVIEW OF HEMATOLOGY (2018)

Add to Collection

Review Infectious Diseases

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)

M. Mikulska et al.

CLINICAL MICROBIOLOGY AND INFECTION (2018)

Add to Collection

Review Geriatrics & Gerontology

Age and immunity: What is immunosenescence?

Graham Pawelec

EXPERIMENTAL GERONTOLOGY (2018)

Add to Collection

Review Immunology

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

Keith A. Sacco et al.

IMMUNOTHERAPY (2018)

Add to Collection

Article Immunology

Bacterial Pneumonia in Older Adults

Oryan Henig et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2017)

Add to Collection

Article Cell Biology

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Editorial Material Hematology

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Ahmet Emre Eskazan et al.

EXPERT REVIEW OF HEMATOLOGY (2017)

Add to Collection

Review Endocrinology & Metabolism

The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies

Waseem Abu-Ashour et al.

BMJ OPEN DIABETES RESEARCH & CARE (2017)

Add to Collection

Article Multidisciplinary Sciences

Immune System Dysfunction in the Elderly

Eduardo Fuentes et al.

ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS (2017)

Add to Collection

Article Oncology

Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study

Anat Gafter-Gvili et al.

LEUKEMIA & LYMPHOMA (2016)

Add to Collection

Review Infectious Diseases

An overview of infectious complications after allogeneic hematopoietic stem cell transplantation

Ugur Sahin et al.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2016)

Add to Collection

Review Immunology

Risk stratification and immunogenetic risk for infections following stem cell transplantation

Agnieszka Wojtowicz et al.

VIRULENCE (2016)

Add to Collection

Article Oncology

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population

JG Perkins et al.

CANCER (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.